Newtyn Management’s Black Diamond Therapeutics BDTX Stock Holding History

Newtyn Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-95,000	Closed	-$413K	–	34
2024 Q3	$413K	Hold	95,000	–	–	0.06%	38
2024 Q2	$443K	Sell	95,000 -30,000	-24%	-$161K	0.08%	37
2024 Q1	$634K	Sell	125,000 -155,000	-55%	-$625K	0.13%	39
2023 Q4	$787K	Buy	280,000 +75,000	+37%	+$176K	0.15%	40
2023 Q3	$588K	Buy	205,000 +5,000	+3%	+$18.4K	0.15%	42
2023 Q2	$1.01M	Sell	200,000 -106,609	-35%	-$218K	0.24%	36
2023 Q1	$579K	Sell	306,609 -8,391	-3%	-$19.3K	0.11%	68
2022 Q4	$567K	Sell	315,000 -35,000	-10%	-$63K	0.12%	60
2022 Q3	$592K	Sell	350,000 -170,000	-33%	-$524K	0.13%	64
2022 Q2	$1.28M	Buy	+520,000	New	+$1.21M	0.24%	56

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Newtyn Management's BDTX Position: Q4 2024 in Review

Newtyn Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 95,000 shares — an estimated $413K sold.

Newtyn Management first reported a position in BDTX in Q2 2022 and held it in 10 quarters. The position peaked at $1.28M in Q2 2022. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

Newtyn Management reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
Newtyn Management sold 95,000 Black Diamond Therapeutics shares in Q4 2024, an estimated $413K.
Newtyn Management first reported a position in Black Diamond Therapeutics in Q2 2022 and held it in 10 quarters.
Newtyn Management's Black Diamond Therapeutics position peaked at $1.28M in Q2 2022.
87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on Newtyn Management's 13F filing for Q4 2024, filed 14 Feb 2025.